Focused on Hematology,
Dedicated to Patients


There are millions of patients whose lives are affected by
and suffer from hematologic diseases. From rare blood
disorders to widespread, chronic disorders, there are a
host of diseases that require creative, new approaches
and a willingness to pioneer new fields of biology.

learn more about our science


We are committed to turning scientific discoveries into
useful therapies that will have a meaningful impact on
the lives of patients and their families. We are pursuing
the development of treatments that will potentially save
lives, alleviate suffering and enable patients to lead
vibrant lives.

learn more about our pipeline


Our team of talented scientists and industry veterans draws 
motivation and meaning from the work we do and the patients 
we hope to help. We are also inspired by a shared drive, tireless 
dedication and desire to make a difference that brings us together 
as colleagues.

learn more about our team

In The News

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and…

read more

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include adolescents Data from all adult…

read more

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP) Oral presentation at ASH meeting of…

read more